Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, OH 44195, USA.
Mult Scler. 2012 Aug;18(8):1074-80. doi: 10.1177/1352458512451512. Epub 2012 Jun 27.
This article describes proceedings from a meeting of the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures (the TF). The TF was appointed by the NMSS Research Programs Advisory Committee with the goal of pooling and analyzing existing datasets to explore the utility of novel disability outcome measures based on the Multiple Sclerosis Functional Composite (MSFC) approach. The TF seeks to determine the suitability of the MSFC approach as a primary clinical outcome measure for registration trials in MS. The TF met in Washington, DC, Dec. 14 and 15, 2011, and provided unanimous support for a collaborative approach involving representatives from academic medicine, the pharmaceutical industry, regulatory agencies, the NMSS and the Critical Path Institute. There was also unanimous agreement that analysis of existing datasets would be useful in making progress toward the objective. The TF placed high value on determining the clinical meaning of individual component measures for the MSFC, and in establishing optimal analysis methods for MSFC so that scores would be more interpretable than the originally recommended z-score method. The background for a collaborative project aimed at developing an improved disability outcome measure is described in this paper.
本文描述了全国多发性硬化症学会(NMSS)临床残疾衡量标准工作组(TF)会议的进展情况。该 TF 由 NMSS 研究计划咨询委员会任命,目标是汇集和分析现有数据集,以探索基于多发性硬化功能综合(MSFC)方法的新型残疾结果衡量标准的效用。TF 旨在确定 MSFC 方法作为多发性硬化症注册试验的主要临床结果衡量标准的适宜性。TF 于 2011 年 12 月 14 日和 15 日在华盛顿特区举行会议,一致支持涉及学术医学、制药业、监管机构、NMSS 和关键路径协会的代表的合作方法。与会者还一致认为,分析现有数据集将有助于朝着目标取得进展。TF 高度重视确定 MSFC 各个组成部分衡量标准的临床意义,并为 MSFC 建立最佳分析方法,以便评分比最初推荐的 z 分数方法更具可解释性。本文介绍了旨在开发改进的残疾结果衡量标准的合作项目的背景。